Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Case Ruling Allows For Launch Of Generic Pepcid Complete

This article was originally published in The Tan Sheet

Executive Summary

The U.S. District Court for the Southern District of New York invalidated a key patent for Johnson & Johnson/Merck's Pepcid Complete, opening the door for Perrigo to enter the market with a private-label equivalent

You may also be interested in...



Pepcid Complete generic debuts

Perrigo expects to ship its OTC Famotidine Complete chewable tablets in the third quarter of 2008 following FDA final approval of its abbreviated new drug application, the Allegan, Mich.-based firm says Feb. 12. The product (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) is comparable to Johnson & Johnson/Merck's Pepcid Complete acid reducer/antacid medicine and will be marketed under store brand labels, Perrigo notes. It expects marketing exclusivity as the first company to file a complete ANDA with a Paragraph IV certification, but has not indicated what the duration will be. "This final approval reflects our continuing investment in new products," CEO Joseph C. Papa says in a release. The launch follows a federal court ruling in 2007 that invalidated a key patent for Pepcid Complete (1"The Tan Sheet" June 11, 2007, p. 5)...

Pepcid Complete generic debuts

Perrigo expects to ship its OTC Famotidine Complete chewable tablets in the third quarter of 2008 following FDA final approval of its abbreviated new drug application, the Allegan, Mich.-based firm says Feb. 12. The product (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) is comparable to Johnson & Johnson/Merck's Pepcid Complete acid reducer/antacid medicine and will be marketed under store brand labels, Perrigo notes. It expects marketing exclusivity as the first company to file a complete ANDA with a Paragraph IV certification, but has not indicated what the duration will be. "This final approval reflects our continuing investment in new products," CEO Joseph C. Papa says in a release. The launch follows a federal court ruling in 2007 that invalidated a key patent for Pepcid Complete (1"The Tan Sheet" June 11, 2007, p. 5)...

Pepcid Complete generic debuts

Perrigo expects to ship its OTC Famotidine Complete chewable tablets in the third quarter of 2008 following FDA final approval of its abbreviated new drug application, the Allegan, Mich.-based firm says Feb. 12. The product (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) is comparable to Johnson & Johnson/Merck's Pepcid Complete acid reducer/antacid medicine and will be marketed under store brand labels, Perrigo notes. It expects marketing exclusivity as the first company to file a complete ANDA with a Paragraph IV certification, but has not indicated what the duration will be. "This final approval reflects our continuing investment in new products," CEO Joseph C. Papa says in a release. The launch follows a federal court ruling in 2007 that invalidated a key patent for Pepcid Complete (1"The Tan Sheet" June 11, 2007, p. 5)...

Related Content

Topics

UsernamePublicRestriction

Register

PS100600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel